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(APL) treated using all-trans-retinoic acid (ATRA) based therapy
will relapse. An analysis of salvage therapy in patients  66 years
old from two sequential European multi-center trials demonstrated
the efﬁcacy of autologous peripheral blood stem cell transplant
(PBSCT) performed during molecular remission.
Since 2004, APL recurred in four patients following ATRA based
therapy. Table 1 (below) summarizes their clinical characteristics.
After achieving molecular remission, the patients received cyclo-
phosphamide 2 gm/m2 for two days followed by G-CSF mobili-
zation. All PBSC products were negative for PML-RARA by RT-
PCR. To date, three patients received stem cell infusions following
cyclophosphamide (60 mg/kg X 2 days) and total body irradiation
(200 cGy X 6).
All three transplanted patients remain in molecular remission 27,
13, and 8 months following PBSCT. Engraftment of WBC oc-
curred at 13, 15 and 18 days, with discharge days of 16, 18, and 20
post-PBSCT. Maximum toxicity was Grade III mucositis (NCI
CTC v.3.0).
PML-RARA negative stem cells can be mobilized in pediatric
patients after arsenic trioxide or FLAG therapy using cyclophos-
phamide and G-CSF. Three patients have durable molecular re-
mission following PBSCT. Autologous PBSCT is an option for
pediatric patients with relapsed APL that avoids the complications
of graft vs host disease, prolonged immunosuppression, and the
higher transplant related mortality of allogeneic transplantation.
Table 1. Clinical characteristcs, salvage therapies and mobilization
outcome.
Age at dx
(yrs)/gender
Sanz Risk
Group1
Length
CR 1
(mos)
Relapse
Site
Re-induction
therapy
# days
harvested
Total
CD34/kg
X 106
14 M High 11 Marrow
 CNS
Arsenic trioxide
 Intrathecal
Ara-C
3 2.19
15 M Intermediate 24 Marrow Arsenic trioxide 3 2.35
2 M Intermediate 14 CNS FLAG2 
Intrathecal Ara-
C and
Methotrexate
1 207.00
12 M Low 26 Marrow Arsenic
Trioxide
1 14.53
1 Sanz, Blood 2000: 96(4), 1247-1253 2 FLAG (ﬂudarabine 25
mg/m2 X 5 days; cytarabine 2 gm/m2 X 5 days; G-CSF)
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HIGH-DOSE THIOTEPA, BUSULFAN, AND CYCLOPHOSPHAMIDE FOR
ALLOGENEIC STEM CELL TRANSPLANTION IN RISK PEDAITRIC PA-
TIENTS WITH HIGH-RISK LEUKEMIAS
Worth, L.L.1, Koontz, S.E.1, Petropoulos, D.1, Tran, H.T.1,
Choroszy, M.S.1, Chan, K.2 1University of Texas M D Anderson Cancer
Center, Houston, TX; 2Texas Transplant Institute, San Antonio, TX.
Between 1992 and 2003, 50 children at M D Anderson Cancer
Center with high-risk leukemias received thiotepa (250 mg/m2 x 3),
busulfan (1 mg/kg q 6 hrs x 12 orally or 0.8 mg/kg q 6 hrs iv x 12),
and cyclophosphamide (60mg/kg x 2) as a preparative regimen for
allogeneic stem cells transplantation. High-risk ALL patients (25)
had abnormal cytogenetics (Ph, 11q23), CR2 after early relapse,
 CR3, or were induction failures. Patients will AML (25) were
included if they had CR 2, MDS, or were induction failures.
Sixteen patients were transplanted with active disease ( 5% blasts
on bone marrow aspirate). Busulfan was given orally until 1999
when the intravenous preparation was available. Stem cell sources
included HLA matched family members (21) and unrelated mar-
row and cord blood (29). Two patients failed to engraft and went
on to receive a second transplant. Neutrophil engraftment (ANC
500) occurred at a median of 17.5 days (range 11-63) and platelet
counts50,000/L at a median of 44.5 days (range 13-394). Grade
3-4 toxicities occurred in 24 patients and were predominantly
esophagitis and mucositis, emesis, and hepatic dysfunction. All
three patients who developed VOD had received busulfan orally.
One patient did not have pharmacokinetics performed secondary
to machine malfunction. One patient had an acceptable AUC. The
ﬁnal patient had an elevated BU dose that was decreased based on
initial pharmacokinetics. Grades I -II acute GVHD was common
(27 patients). Grades III-IV occurred in 5 patients. Five patients
developed limited chronic GVHD, and 9 patients developed ex-
tensive chronic GVHD. Nineteen patients are alive and well a
median of 7.0 years (range 3.0 - 13.9). Thirty-one patients died of
recurrent disease (13), infection (6), GVHD (5), VOD (3), other
causes (4). The two patients who failed to engraft and underwent a
second transplant died of disease recurrence. Children with high-
risk leukemias are difﬁcult to cure even with high-dose chemother-
apy and stem cell transplantation. Of the 16 patients transplanted
with active disease, only the patients with AML are long term
survivors, suggesting that this regimen alone will not result in a
cure, but that additional strategies are required for children with
active ALL. This chemotherapeutic regimen had some signiﬁcant
toxicities, however, after the development of intravenous busulfan,
this regimen had a signiﬁcant decrease in nausea and there were no
incidence of VOD suggesting further evaluation.
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A NOVEL RAG-1 NULL MUTANT DISPLAYS SEGREGATION OF DNA
CLEAVAGE INTO TRANSPOSITION ACTIVITY IN THREE CHILDREN WITH
T-B-NKSCID
Xiao, T.Z.1, Dunn, E.A.1, Yannone, S.M.2, Cowan, M.J.1 1Pediatric
Bone Marrow Transplant Division, UCSF Children’s Hospital, 505
Parnassus Ave, San Francisco, CA; 2Life Sciences Division, Department
of Molecular Biology, Lawrence Berkeley National Laboratory, 1 Cyclo-
tron Road, Berkeley, CA.
RAG (recombination activating gene)-1 and RAG-2 initiate
V(D)J recombination by cleaving DNA at recombination signal
sequences (RSS) through sequential nicking and transesteriﬁcation
reactions to yield blunt signal and coding ends terminating in DNA
hairpin structures. Ubiquitous DNA double strand repair factors in
the non-homologous ending joining (NHEJ) pathway then medi-
ate the rejoining of broken DNA. Severe combined immunodeﬁ-
ciency disease (SCID) comprises a heterogeneous group of primary
immunodeﬁciencies, a proportion of which are due to mutations in
RAG-1, RAG-2 or in NHEJ factors, respectively. Here, we report
a novel RAG-1 null mutation, R776W, identiﬁed in three familial
related children from the Dine´ Native American tribe who mani-
fest a classic T-B-NKSCID phenotype and engraftment of ma-
ternal T cells. Unlike Artemis mutations among Athabascan-speak-
ing Native Americans, which trigger accumulation of the hairpin
structure, this RAG-1 null mutant evokes impaired DNA cleavage
and binding activity in vitro by preferentially diminishing hairpin
formation. Moreover, the V(D)J recombination efﬁciency of this
mutant is also reduced as assessed by an enhanced green ﬂuores-
cent protein (EGFP) based V(D)J recombination assay. However,
the catalysis of other DNA strand transfer reaction, such as trans-
position, is not substantially affected by this RAG-1 mutant. These
results indicate that dysfunction of RAG-1 is responsible for the
T-B-NKSCID phenotype. Segregation of RAG-1 mediated DNA
cleavage activity into its transposition activity casts a new light on
RAG-1’s roles in V(D)J recombination and translocation.
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FEASIBILITY OF AUTOLOGOUS STEM CELL TRANSPLANT FOLLOWED
BY REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION
FOR HIGH RISK NEUROBLASTOMA: A SINGLE INSTITUTION PILOT
STUDY
Yamashiro, D.J.1, Lee, A.1, Bhatia, M.1, Glade-Bender, J.1,
Qualter, E.1, Militano, O.1, Harrison, L.A.1, Davenport, V.1,
Cheung, K.1, Bradley, M.B.1, Garvin, J.H.1, Del Toro, G.1,
Cairo, M.S.1 1Columbia University, New York, NY.
Background: Autologous stem cell transplant (AutoSCT) has
improved the outcome for children with high risk (HR) neuroblas-
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